
ADiTx Therapeutics Market Cap | ADTX
As of November 22, 2026 ADiTx Therapeutics has a market cap of $ 374
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap ADiTx Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.6 K | 8.98 M | 2.94 K | 42.7 K | 141 K | 25.7 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.7 M | 2.94 K | 5.82 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Auris Medical Holding Ltd.
EARS
|
8.29 M | - | -1.77 % | $ 39.2 M | ||
|
Dicerna Pharmaceuticals, Inc.
DRNA
|
1.67 B | - | 0.34 % | $ 2.98 B | ||
|
ERYTECH Pharma S.A.
ERYP
|
24.2 M | - | 1.3 % | $ 27.7 M | ||
|
GW Pharmaceuticals plc
GWPH
|
4.79 B | - | - | $ 6.81 B | ||
|
22nd Century Group
XXII
|
541 K | $ 0.32 | -19.83 % | $ 58.9 K | ||
|
Kadmon Holdings, Inc.
KDMN
|
813 M | - | - | $ 1.7 B | ||
|
Liminal BioSciences
LMNL
|
2.65 M | - | - | $ 256 M | ||
|
argenx SE
ARGX
|
42.4 B | $ 926.42 | -1.66 % | $ 56.8 B | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
114 M | $ 2.33 | -7.25 % | $ 19.8 M | ||
|
Zai Lab Limited
ZLAB
|
21.6 B | $ 21.01 | -4.16 % | $ 23 B | ||
|
Neos Therapeutics, Inc.
NEOS
|
80.6 M | - | -2.54 % | $ 57.2 M | ||
|
Zentalis Pharmaceuticals
ZNTL
|
192 M | $ 1.37 | 0.74 % | $ 98.5 M | ||
|
Zoetis
ZTS
|
56.1 B | $ 78.81 | -2.47 % | $ 34.9 B | ||
|
Odonate Therapeutics, Inc.
ODT
|
759 M | - | -3.18 % | $ 58.5 M | ||
|
Orphazyme A/S
ORPH
|
236 M | - | -2.25 % | $ 31.3 M | ||
|
Osmotica Pharmaceuticals plc
OSMT
|
262 M | - | -10.74 % | $ 89.9 M | ||
|
Pandion Therapeutics, Inc.
PAND
|
419 M | - | - | $ 1.77 B | ||
|
Xenetic Biosciences
XBIO
|
4.37 M | $ 1.47 | -4.55 % | $ 2.5 M | ||
|
Translate Bio, Inc.
TBIO
|
1.23 B | - | - | $ 2.81 B | ||
|
Trillium Therapeutics Inc.
TRIL
|
1.1 B | - | - | $ 1.94 B | ||
|
Urovant Sciences Ltd.
UROV
|
273 B | - | - | $ 532 M | ||
|
Acceleron Pharma Inc.
XLRN
|
6.89 B | - | - | $ 10.9 B | ||
|
Zogenix, Inc.
ZGNX
|
1.02 B | - | -4.97 % | $ 664 M | ||
|
Yunhong International
ZGYH
|
18.2 M | - | 0.10 % | $ 92.2 M | ||
|
ZIOPHARM Oncology, Inc.
ZIOP
|
790 M | - | -7.58 % | $ 264 M | ||
|
Taysha Gene Therapies
TSHA
|
1.46 B | $ 3.71 | -1.72 % | $ 1.19 B | ||
|
Vericel Corporation
VCEL
|
1.88 B | $ 57.41 | -1.46 % | $ 2.89 B | ||
|
Vir Biotechnology
VIR
|
1.02 B | $ 8.37 | -5.64 % | $ 1.16 B | ||
|
Veracyte
VCYT
|
3.04 B | $ 25.08 | 0.16 % | $ 1.97 B | ||
|
Viking Therapeutics
VKTX
|
3.18 B | $ 24.72 | -4.35 % | $ 2.79 B | ||
|
Vanda Pharmaceuticals
VNDA
|
358 M | $ 3.44 | -6.27 % | $ 203 M | ||
|
VistaGen Therapeutics
VTGN
|
21.7 M | $ 0.16 | -12.33 % | $ 6.09 M | ||
|
Voyager Therapeutics
VYGR
|
241 M | $ 1.52 | -5.9 % | $ 89.2 M | ||
|
Verrica Pharmaceuticals
VRCA
|
66.7 M | $ 2.74 | -5.03 % | $ 29.2 M | ||
|
Wave Life Sciences Ltd.
WVE
|
2.6 B | $ 2.56 | -6.07 % | $ 432 M | ||
|
XBiotech
XBIT
|
70.4 M | $ 1.75 | 4.17 % | $ 53.4 M | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
855 M | $ 1.37 | -7.43 % | $ 922 M | ||
|
Adial Pharmaceuticals
ADIL
|
1.31 M | $ 3.15 | -35.42 % | $ 2.11 M | ||
|
ADMA Biologics
ADMA
|
3.78 B | $ 13.18 | -1.2 % | $ 3.14 B | ||
|
Exicure
XCUR
|
29 M | $ 0.96 | -7.24 % | $ 6.05 M | ||
|
Xencor
XNCR
|
892 M | $ 33.48 | -1.56 % | $ 2.49 B | ||
|
Cortexyme
CRTX
|
70 M | - | -1.05 % | $ 67.1 M | ||
|
Burford Capital Limited
BUR
|
2.78 B | $ 3.24 | -5.55 % | $ 710 M | ||
|
Daré Bioscience
DARE
|
16.9 M | $ 0.41 | -9.93 % | $ 4.58 M | ||
|
Fate Therapeutics
FATE
|
187 M | $ 0.92 | -9.07 % | $ 109 M | ||
|
Greenwich LifeSciences
GLSI
|
386 M | $ 19.09 | -3.54 % | $ 258 M | ||
|
Halozyme Therapeutics
HALO
|
9.66 B | $ 91.28 | -1.89 % | $ 10.9 B | ||
|
Hutchison China MediTech Limited
HCM
|
12 B | $ 13.18 | -2.04 % | $ 11.3 B | ||
|
Aptorum Group Limited
APM
|
6.69 M | - | - | $ 5.72 M | ||
|
iBio
IBIO
|
142 M | $ 0.83 | 3.01 % | $ 86.4 M |